# Thalidomide-Dexamethasone for Multiple Myeloma

> **NCT00038090** · PHASE2,PHASE3 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 83 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00038090
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038090, "Thalidomide-Dexamethasone for Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00038090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*